PANEXIA®: Hereditary Testing for Pancreatic Cancer
PANEXIA® is a genetic test specifically created to detect mutations in genes that result in an increased risk of pancreatic cancer, offering patients and their families insight into their risk of hereditary cancers. PANEXIA® is a simple blood test that analyzes the PALB2 and BRCA2 genes, which are most commonly identified in families with hereditary pancreatic cancer.
The PANEXIA® test results provide information for patients and their family members about the inherited risks of pancreatic cancer, as well as breast, ovarian, and other cancers. This knowledge may allow at-risk family members the opportunity to lower their risks for some of these cancers through surveillance, preventative options or lifestyle choices.
Myriad has developed a Hereditary Cancer Quiz that patients and can use to help identify potential candidates for genetic testing using PANEXIA®.
Benefits of PANEXIA® Testing
The results of the PANEXIA® test enable healthcare professionals to develop individualized medical management plans to:
- Personalize patient care by targeting screening and surveillance specifically to individuals with a PALB2 or BRCA2 gene mutation;
- Improve compliance with tailored screening recommendations and preventive measures;
- Improve outcomes through prevention, earlier diagnosis and treatment of specific cancers;
- Counsel patients and their family members on the underlying cause of mutation-related cancers; and
- Avoid unnecessary interventions for family members who do not test positive for the mutation known to be in the family.
Medical Management and PANEXIA®
If PANEXIA® testing confirms the presence of a PALB2 or BRCA2 mutation, the following medical management options may help reduce cancer risk and may either delay the onset of cancer, detect it at an earlier, more treatable stage or even prevent it:
Positive PALB2 Gene Mutation Results Indicate:
- Increased surveillance for pancreatic cancer
- Increased surveillance for breast cancer
Positive BRCA2 Gene Mutation Results Indicate:
- Increased surveillance for pancreatic, breast and ovarian cancer
- Risk reducing medications
- Prophylactic surgery
For more healthcare professional information, please visit MyriadPro.com.
NOTE: Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare professional.